Repository logo
 
Publication

Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat

2012-01Journal article Open access
Simple item page
dc.contributor.authorTeixeira, M.
dc.contributor.authorRodrigues-Santos, P.
dc.contributor.authorGarrido, P.
dc.contributor.authorCosta, E.
dc.contributor.authorParada, B.
dc.contributor.authorSereno, J.
dc.contributor.authorAlves, R.
dc.contributor.authorBelo, L.
dc.contributor.authorTeixeira, F.
dc.contributor.authorSantos-Silva, A.
dc.contributor.authorReis, F.
dc.date.accessioned2021-09-21T10:24:08Z
dc.date.available2021-09-21T10:24:08Z
dc.date.issued2012-01
dc.description.abstractObjective: Recombinant human erythropoietin (rhEPO) therapy under circumstances of moderate chronic renal failure (CRF), with yet lower kidney and heart lesion, may have a protective cardiac effect beyond the correction of anemia, whose mechanism deserves better elucidation, namely by clarifying the impact on gene expression profile of markers of apoptosis, inflammation, proliferation, angiogenesis, and lesion/stress in the heart. Materials and Methods: Four groups of rats were studied over a period of 15 weeks (n=7 each): control-without surgery and without drug treatment; rhEPO-treated with 50 IU/kg/week of rhEPO-beta; CRF-submitted to partial nephrectomy (3/4); CRF + rhEPO-CRF with rhEPO treatment after the 3rd week of surgery. The heart was collected in order to evaluate the gene expression, by real-time qPCR, of markers of apoptotic machinery, inflammation/immunology, proliferation/ angiogenesis, and lesion/stress. Results: The main findings obtained were (a) CRF rats have demonstrated overexpression of EPO-R in the heart without changes on EPO expression, together with overexpression of Bax/Bcl2 ratio, PCNA, and IL-2; (b) rhEPO therapy on the heart of the rats with CRF induced by partial 3/4 nephrectomy promoted nonhematopoietic protection, demonstrated by the apoptosis prevention, viewed by the Bax/Bcl2 balance, by the promotion of proliferation, due to PCNA increment, and by the immunomodulatory action, expressed by a trend to prevent the IL-2 increment. Conclusion: In this model of moderate CRF, rhEPO treatment showed important cardiac nonhematopoietic effects, expressed mainly by the antiapoptotic and the proproliferative action, suggesting that early rhEPO therapy in moderate stages of CRF might have further therapeutic benefits.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.4103/0975-7406.92743pt_PT
dc.identifier.eid84856859990
dc.identifier.issn0976-4879
dc.identifier.urihttp://hdl.handle.net/10400.14/35042
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/pt_PT
dc.subjectApoptosispt_PT
dc.subjectCardiovascular protectionpt_PT
dc.subjectGene expressionpt_PT
dc.subjectModerate chronic renal failurept_PT
dc.subjectProliferation/angiogenesispt_PT
dc.titleCardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the ratpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage83pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage76pt_PT
oaire.citation.titleJournal of Pharmacy and Bioallied Sciencespt_PT
oaire.citation.volume4pt_PT
person.familyNameRodrigues Santos
person.familyNameCosta
person.familyNameParada
person.familyNameAlves
person.familyNameBelo
person.familyNameTeixeira
person.familyNameSantos-Silva
person.familyNameReis
person.givenNamePaulo
person.givenNameElisio
person.givenNameBelmiro
person.givenNameRui
person.givenNameLuís
person.givenNameFrederico
person.givenNameAlice
person.givenNameFlávio
person.identifier55546
person.identifier606269
person.identifier2208278
person.identifier1368242
person.identifier.ciencia-id4311-1E7F-9AA8
person.identifier.ciencia-id6612-4AB7-363B
person.identifier.ciencia-id2B15-FEA9-E526
person.identifier.ciencia-id8313-13F7-828C
person.identifier.ciencia-idC319-EED1-E15D
person.identifier.ciencia-id3A11-3945-4DC4
person.identifier.orcid0000-0001-7519-1620
person.identifier.orcid0000-0003-1158-1480
person.identifier.orcid0000-0002-9911-4926
person.identifier.orcid0000-0003-3922-3618
person.identifier.orcid0000-0002-3941-6850
person.identifier.orcid0000-0002-2601-0923
person.identifier.orcid0000-0002-2565-3169
person.identifier.orcid0000-0003-3401-9554
person.identifier.ridM-3175-2013
person.identifier.ridK-1990-2013
person.identifier.ridN-2759-2013
person.identifier.ridK-5878-2013
person.identifier.ridK-2326-2013
person.identifier.scopus-author-id37021720200
person.identifier.scopus-author-id7402527214
person.identifier.scopus-author-id56024083800
person.identifier.scopus-author-id56219007200
person.identifier.scopus-author-id6602879850
person.identifier.scopus-author-id7102746390
person.identifier.scopus-author-id6603836490
person.identifier.scopus-author-id7004405551
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication73498c7f-d44b-4a56-9b63-c7cb5b738811
relation.isAuthorOfPublication48424466-ddc6-4188-8745-8e72e4bdd1f9
relation.isAuthorOfPublication8cb396e5-8aed-4597-9e86-799cf9493c37
relation.isAuthorOfPublicationcdf71243-0cb2-4346-be90-e4de5382e352
relation.isAuthorOfPublication3654b7b5-7ad2-4f2f-9114-93dc094f8e9e
relation.isAuthorOfPublication63401f5d-a17a-4607-b110-a440cef8a6e9
relation.isAuthorOfPublication190165a4-a22a-47b8-a0bd-f6e7a93cba2d
relation.isAuthorOfPublicationcd330ef7-3a65-4bc7-88d0-d6dc8b3185d1
relation.isAuthorOfPublication.latestForDiscovery63401f5d-a17a-4607-b110-a440cef8a6e9

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
JPharmBioallSci4176_4081662_112016.pdf
Size:
528.41 KB
Format:
Adobe Portable Document Format
Download

Collections

CIIS - Contribuições em Revistas Científicas / Contribution to Journals